Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer

Published:2021-10-18 Issue:20 Volume:64 Page:14968-14982
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Leblanc Eric¹,Ban Fuqiang¹,Cavga Ayse Derya²,Lawn Sam¹,Huang Chia-Chi Flora¹,Mohan Sankar³,Chang Matthew E. K.⁴,Flory Mark R.⁴,Ghaidi Fariba¹,Lingadahalli Shreyas¹,Chen Gang³,Yu Ivan Pak Lok¹,Morin Hélène¹,Lallous Nada¹,Gleave Martin E.¹,Mohammed Hisham⁴,Young Robert N.³,Rennie Paul S.¹,Lack Nathan A.¹²^ORCID,Cherkasov Artem¹^ORCID

Affiliation:

1. Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, British Columbia V6H 3Z6, Canada

2. School of Medicine, Koç University, Rumelifeneri Yolu, Istanbul 34450, Turkey

3. Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada

4. Knight Cancer Institute, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon 97239, United States

Funder

Canadian Institutes of Health Research

Prostate Cancer Canada

U.S. Department of Defense

Canadian Cancer Society Research Institute

Publisher

American Chemical Society (ACS)